Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Giulia OrsiAlessandro CavaliereGiampaolo TortoraSara LonardiMarina MacchiniMariacristina Di MarcoGuido GiordanoEnrico VasileMario ScartozziSilvia BozzarelliSilvia NoventaMaria Grazia RodriquenzAnna Maria MilitelloIlario Giovanni RapposelliIngrid GarajovàStefania De LorenzoBarbara MerelliAlessandro BittoniLisa SalvatoreLetizia ProcaccioChiara ParatoreAndrea SpallanzaniUmberto PerettiMonica NigerElisa GiommoniIlaria BernardiniEmiliano TamburiniKatia BernardinoLaura FortiMaria Maddalena ValenteStefano CascinuMichele MilellaMichele ReniPublished in: British journal of cancer (2022)
This study highlighted the beneficial role of platinum agents in gBRCA1-2pv PDAC patients also in second-line treatment setting. However, our data suggest that early use of 3- and 4-drug platinum-based chemotherapy combinations provides a survival outcome advantage.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- emergency department
- copy number
- gene expression
- electronic health record
- squamous cell carcinoma
- big data
- machine learning
- patient reported outcomes
- dna methylation
- mesenchymal stem cells
- combination therapy
- patient reported
- drug induced
- bone marrow
- genome wide